Independent Bank Group, Inc. Reports First Quarter Financial Results and Declares Quarterly Dividend
McKINNEY, Texas–(BUSINESS WIRE)–Independent Bank Group, Inc. (NASDAQ: IBTX) today announced net income of $24.2 million, or $0.58 per diluted share,... Read more.
Equity Bancshares, Inc. Expands Footprint Within Home State of Kansas
Company will acquire KansasLand Bank, add Western and Central Kansas locations WICHITA, Kan.–(BUSINESS WIRE)–#EquityBankUSA–Equity Bancshares,... Read more.
Browning West and Glenn Chamandy Comment on Gildan Activewear’s Defensive and Reactionary Board Refreshment
Gratified That Board Leadership, Including the Chairman and Every Committee Chair, Has Seemingly Acknowledged Their Many Failures by Resigning En Masse Question... Read more.
Seagate Drives Progress on Its Renewable Energy and Circularity Programs
Company’s FY2023 ESG Performance Report details progress towards a sustainable, inclusive, and ethical datasphere FREMONT, Calif.–(BUSINESS WIRE)–Seagate... Read more.
Alterra Mountain Company Releases Its 2023 Impact Report
DENVER–(BUSINESS WIRE)–Today, Alterra Mountain Company released its second annual Forward Stance Impact Report, outlining its ongoing commitment to Social... Read more.
ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting
Presentation of industry-leading T-cell delivery in NHPs Oral presentation highlighting an all-RNA system enabling exon-sized genome insertions CAMBRIDGE, Mass.–(BUSINESS... Read more.
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NGN-401 has been generally well-tolerated by three patients with multiple months of follow-up NEW YORK–(BUSINESS WIRE)–Neurogene Inc. (Nasdaq: NGNE),... Read more.
Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Company will highlight developments enabled by its CRISPR by Design™ approach to engineer novel in vivo genetic medicines, including for ophthalmic diseases ALAMEDA,... Read more.
Driven Brands Holdings Inc. to host first quarter earnings conference call on May 2, 2024
CHARLOTTE, N.C.–(BUSINESS WIRE)–Driven Brands Holdings Inc. (NASDAQ: DRVN) will release its first quarter 2024 earnings before the market opens on May... Read more.
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
RICHMOND, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of... Read more.